Thus, it will be crucial to examine the possibility to combine Ivacaftor (or other CFTR potentiators) with cysteamine (or other yet-to-be-developed TGM2 inhibitors) and EGCG (or alternative autophagy enhancers) with the scope of interrupting the self-enforcing circuitry that likely intervenes in CD. This evidence concerns the gene CFTR and Cowden disease.